New oral anticoagulants for the treatment of venous thromboembolism

Understanding differences and similarities

Paul P Dobesh, John Fanikos

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Venous thromboembolism (VTE) is a major cause of morbidity, mortality, and healthcare expenditure. In the United States, approximately 0.1 % of the population experiences an initial VTE event each year. Anticoagulation therapy is the cornerstone of acute VTE treatment and for prevention of recurrent VTE events. Conventional anticoagulants, including heparin, low-molecular-weight heparins, fondaparinux, and vitamin K antagonists are widely used but have limitations. Newer oral anticoagulant agents, including direct thrombin inhibitors (e.g., dabigatran etexilate) and direct factor Xa inhibitors (e.g., rivaroxaban, apixaban, and edoxaban) have been developed to attempt to overcome some of the limitations of conventional anticoagulant therapy. These new oral agents have been evaluated for safety and efficacy in large, randomized clinical trials in the treatment and secondary prevention of VTE with results that are comparable to conventional therapy. Dabigatran, rivaroxaban, apixaban, and edoxaban are important new treatment options for patients with VTE. In this review, we compare these new agents and their associated clinical trials in VTE treatment.

Original languageEnglish (US)
Pages (from-to)2015-2032
Number of pages18
JournalDrugs
Volume74
Issue number17
DOIs
StatePublished - Jan 1 2014

Fingerprint

Venous Thromboembolism
Anticoagulants
Therapeutics
Antithrombins
Vitamin K
Low Molecular Weight Heparin
Health Expenditures
Secondary Prevention
Heparin
Randomized Controlled Trials
Clinical Trials
Morbidity
Delivery of Health Care
Safety
Mortality
Population

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

New oral anticoagulants for the treatment of venous thromboembolism : Understanding differences and similarities. / Dobesh, Paul P; Fanikos, John.

In: Drugs, Vol. 74, No. 17, 01.01.2014, p. 2015-2032.

Research output: Contribution to journalReview article

@article{272e3b3cdbe6419fb2ff7a2f92eb84b1,
title = "New oral anticoagulants for the treatment of venous thromboembolism: Understanding differences and similarities",
abstract = "Venous thromboembolism (VTE) is a major cause of morbidity, mortality, and healthcare expenditure. In the United States, approximately 0.1 {\%} of the population experiences an initial VTE event each year. Anticoagulation therapy is the cornerstone of acute VTE treatment and for prevention of recurrent VTE events. Conventional anticoagulants, including heparin, low-molecular-weight heparins, fondaparinux, and vitamin K antagonists are widely used but have limitations. Newer oral anticoagulant agents, including direct thrombin inhibitors (e.g., dabigatran etexilate) and direct factor Xa inhibitors (e.g., rivaroxaban, apixaban, and edoxaban) have been developed to attempt to overcome some of the limitations of conventional anticoagulant therapy. These new oral agents have been evaluated for safety and efficacy in large, randomized clinical trials in the treatment and secondary prevention of VTE with results that are comparable to conventional therapy. Dabigatran, rivaroxaban, apixaban, and edoxaban are important new treatment options for patients with VTE. In this review, we compare these new agents and their associated clinical trials in VTE treatment.",
author = "Dobesh, {Paul P} and John Fanikos",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s40265-014-0301-x",
language = "English (US)",
volume = "74",
pages = "2015--2032",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "17",

}

TY - JOUR

T1 - New oral anticoagulants for the treatment of venous thromboembolism

T2 - Understanding differences and similarities

AU - Dobesh, Paul P

AU - Fanikos, John

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Venous thromboembolism (VTE) is a major cause of morbidity, mortality, and healthcare expenditure. In the United States, approximately 0.1 % of the population experiences an initial VTE event each year. Anticoagulation therapy is the cornerstone of acute VTE treatment and for prevention of recurrent VTE events. Conventional anticoagulants, including heparin, low-molecular-weight heparins, fondaparinux, and vitamin K antagonists are widely used but have limitations. Newer oral anticoagulant agents, including direct thrombin inhibitors (e.g., dabigatran etexilate) and direct factor Xa inhibitors (e.g., rivaroxaban, apixaban, and edoxaban) have been developed to attempt to overcome some of the limitations of conventional anticoagulant therapy. These new oral agents have been evaluated for safety and efficacy in large, randomized clinical trials in the treatment and secondary prevention of VTE with results that are comparable to conventional therapy. Dabigatran, rivaroxaban, apixaban, and edoxaban are important new treatment options for patients with VTE. In this review, we compare these new agents and their associated clinical trials in VTE treatment.

AB - Venous thromboembolism (VTE) is a major cause of morbidity, mortality, and healthcare expenditure. In the United States, approximately 0.1 % of the population experiences an initial VTE event each year. Anticoagulation therapy is the cornerstone of acute VTE treatment and for prevention of recurrent VTE events. Conventional anticoagulants, including heparin, low-molecular-weight heparins, fondaparinux, and vitamin K antagonists are widely used but have limitations. Newer oral anticoagulant agents, including direct thrombin inhibitors (e.g., dabigatran etexilate) and direct factor Xa inhibitors (e.g., rivaroxaban, apixaban, and edoxaban) have been developed to attempt to overcome some of the limitations of conventional anticoagulant therapy. These new oral agents have been evaluated for safety and efficacy in large, randomized clinical trials in the treatment and secondary prevention of VTE with results that are comparable to conventional therapy. Dabigatran, rivaroxaban, apixaban, and edoxaban are important new treatment options for patients with VTE. In this review, we compare these new agents and their associated clinical trials in VTE treatment.

UR - http://www.scopus.com/inward/record.url?scp=84922079881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922079881&partnerID=8YFLogxK

U2 - 10.1007/s40265-014-0301-x

DO - 10.1007/s40265-014-0301-x

M3 - Review article

VL - 74

SP - 2015

EP - 2032

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 17

ER -